Please assess the completion status of the following clinical trial:

Trial Title: Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese participant~* Good health or any underlying chronic illness is documented to be in stable condition~* Revaccination Group: received one documented PNEUMOVAX™ 23 vaccination at least 5 years before enrollment in the study~* Primary Vaccination Group: no prior history with PNEUMOVAX™ 23 vaccination Exclusion Criteria:~* Known allergy or sensitivity to any of the components of the study vaccine~* History of pneumococcal conjugate vaccination~* Known or suspected immune dysfunction, immunosuppression, or autoimmune disease. Participants with a history of cancer who are not actively treated and not immunosuppressed will be eligible~* Functional or anatomic asplenia~* Received immunoglobulin within 6 months before study vaccine or is planned during the study~* Received any investigational drugs or vaccines within 2 months before study vaccination~* History of pneumococcal disease (positive culture from blood or other normally sterile site)~* Thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection~* History of convulsion~* Previously diagnosed with immunodeficiency or has a close relative with congenital immune deficiency~* Participating in any other clinical trial

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: 89 Years
- Healthy Volunteers: t

Study Arms:
- Revaccination Group (Type: EXPERIMENTAL): 0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who received an initial vaccination at least 5 years prior
- Primary Vaccination Group (Type: EXPERIMENTAL): 0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who have never received PNEUMOVAX™ 23 vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).